Lazard Announces Leadership Appointments in UK Investment Banking
9.9.2019 23:30:00 EEST | Business Wire | Press release
Lazard Ltd (NYSE: LAZ) announced today that it has named Cyrus Kapadia as Chief Executive Officer (CEO) of Lazard Investment Banking in the UK and William Rucker, CEO of the business since 2004, as Chairman, effective immediately. Archie Norman, Chairman of the business since 2013, will continue to serve Lazard as a Special Adviser to Lazard’s CEO.
“William has successfully built and led one of our firm’s most important investment banking franchises in his career at Lazard over the past 30 years,” said Kenneth M. Jacobs, Chairman and CEO of Lazard. “This transition will allow him to focus his efforts as a preeminent adviser to our UK clients.”
“Cyrus is an experienced and trusted adviser to clients, and has played a key role in the recruitment and retention of our people, as well as the evolution, technology advancements and diversification of our business in the UK,” said Peter Orszag, CEO of Lazard Financial Advisory. “In his new role, he will focus on the continued growth of our UK business and on achieving even closer cooperation globally on behalf of our clients.”
“Archie has made invaluable contributions to the firm as Chairman of UK Investment Banking for the past six years, and we thank him for all that he has accomplished,” said Mr. Jacobs. “We look forward to continuing to benefit from his sage advice.”
Mr. Kapadia, most recently Deputy Head of UK Investment Banking, joined Lazard in 1996. He has worked with clients across numerous industry sectors and leads the Technology, Media and Telecommunications Advisory Group in London, one of Lazard’s most active teams in the UK. Mr. Kapadia has had a wide range of corporate finance experience including providing advice to many of the UK's largest companies and private equity sponsors.
Mr. Rucker has served as CEO of Lazard’s Investment Banking business in the UK for the past 15 years. He began his investment banking career at Lazard in 1987. As Chairman, he will continue to work closely with Mr. Kapadia and the UK Investment Banking team, focusing in particular on key client relationships and growth initiatives.
Mr. Norman, a Senior Adviser for Lazard Investment Banking in the UK since 2003, has served as Chairman of Lazard UK Investment Banking since 2013. He was appointed Chairman of Marks & Spencer in October 2017.
Lazard in London is a principal office of the firm’s global network. It has been a major presence in London's financial center since 1877, and added institutional asset management services in 1953. Located in the heart of Mayfair, it is one of Lazard's largest offices, with senior professionals representing all of Lazard's advisory services.
Lazard’s UK Investment Banking business has advised or continues to advise on a number of significant transactions. These include advising Blackstone, KIRKBI and the Canada Pension Plan Investment Board on its acquisition of Merlin Entertainments; Saputo on its acquisition of Dairy Crest; Takeaway.com on its acquisition of JustEat, PLC; WPP on the sale of 60% of Kantar to Bain Capital; Smith & Nephew on its acquisition of Osiris Therapeutic; Daily Mail Trust Group on the sale of its shares in Euromoney PLC; and Merck on its global alliance with GSK.
About Lazard
Lazard, one of the world’s preeminent financial advisory and asset management firms, operates from 43 cities across 27 countries in North America, Europe, Asia, Australia, Central and South America. With origins dating to 1848, the firm provides advice on mergers and acquisitions, strategic matters, restructuring and capital structure, capital raising and corporate finance, as well as asset management services to corporations, partnerships, institutions, governments and individuals. For more information about Lazard, please visit www.lazard.com. Follow Lazard at @Lazard.
LAZ-FAPE
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190909005898/en/
Contact information
Media contacts:
Jenna Ward, +44 21 7187 2305
jenna.ward@lazard.com
Judi Frost Mackey, +1 212 632 1428
judi.mackey@lazard.com
Investor contact:
Alexandra Deignan, +1 212 632 6886
alexandra.deignan@lazard.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fortegra Completes Acquisition by DB Insurance29.5.2026 23:30:00 EEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 23:01:00 EEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom